Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers

Publication

Presentation

October 23, 2026

Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers

Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers

Download the ESMO 2026 poster (PDF)

Related articles

November 9, 2026

Iambic to participate in Jefferies Global Healthcare Conference

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026

October 26, 2026

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers

Iambic Announces Pricing of Initial Public Offering

October 14, 2026

Iambic Announces Pricing of Initial Public Offering

Let's work together

Leverage the Iambic discovery process for your program. Reach out to us at partnerships@iambic.ai.